CLOSTRIDIUM HISTOLYTICUM ENZYMES AND METHODS FOR THE USE THEREOF

26 Feb 2026 ABSTRACT The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

The Problem

OF THE INVENTION Collagen is the major structural constituent of mammalian organisms and makes up a large portion of the total protein content of skin and other parts of the animal body. In 10 humans, it is particularly important in the processes of wound healing process and natural aging. Various skin traumas, including burns, surgery, and infection, are characterized by the accumulation of fibrous tissue rich in collagen and having increased proteoglycan content. In addition to the replacement of the normal tissue which has been damaged or destroyed, excessive and disfiguring deposits of new tissue sometimes form during the healing process. 15 The excess collagen deposition has been attributed to a disturbance in the balance between collagen synthesis and collagen degradation. Diseases and conditions associated with excess collagen deposition and the erratic accumulation of fibrous tissue rich in collagen can be referred to as “collagen-mediated diseases.” Collagenase, an enzyme that has the specific ability to digest collagen, has been 20 used to treat a variety of collagen-mediated diseases, including, for example, Dupuytren’s contracture‘s contracture, Peyronie’s disease, lipoma and adhesiv

In existing solutions, practitioners face limitations in achieving desired outcomes efficiently. This invention directly addresses these gaps by introducing novel technical approaches and mechanisms.

What This Invention Does

DETAILED DESCRIPTION OF THE INVENTION The words “a” or “an” are meant to encompass one or more, unless otherwise specified. For example, “a hemoloytic toxin” refers to one or more hemolytic toxins. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell culture, molecular biology, microbiology, cell biology, and wo 2013/106510 PCT/US2013/020940 26 Feb 2026 9 Biology”, John Wilcy and Sons; Methods in Enzymology (several volumes); Methods in Cell contents of each of which are expressly incorporated by reference herein.

The integration of these technical elements creates a system capable of delivering improved performance over existing alternatives. The inventors have identified and implemented solutions to key challenges that have limited previous approaches in this field.

Key Features

Innovative Technical Integration. The system seamlessly combines multiple functional components to work as a coordinated whole, enabling capabilities that would be difficult or impossible with standalone elements.

Dynamic Parameter Management. The invention includes mechanisms for adapting operational parameters based on conditions and requirements, allowing for optimized performance across diverse scenarios.

Enhanced Efficiency and Capability. Through its novel architecture and control mechanisms, the system achieves superior performance metrics compared to conventional approaches in the field.

Who Is Behind It?

Auxilium International Holdings, Inc. has brought this innovation to the patent system with expertise from a skilled team of inventors: Herber, Wayne K.. This represents their commitment to advancing technology in this important field.

Why It Matters

This patent application demonstrates significant innovation in an important technical area. The solutions described in the specification have the potential to improve how practitioners approach problems and deliver value in real-world applications.

The international patent classifications include C12N 9/52 (2006.01). These codes situate the invention within the broader landscape of technological innovation and represent important areas of advancement.

---

AU 2026201446 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Clostridium histolyticum produces potent collagenases that selectively break down collagen, making them therapeutically valuable for conditions involving excessive fibrous tissue deposition. Recombinant production of these enzymes enables consistent dosing for diseases such as Dupuytren’s contracture and Peyronie’s disease, where collagen cords or plaques cause significant functional impairment.